source
- Windward Bio launches on Nasdaq after $175 million IPO, secures $50 million from SanofiWindward Bio, a biotech developing drugs for respiratory diseases, completed its initial public offering and began trading on Nasdaq. The offering raised $175 million, with the stock opening at $1…
- Clene Nanomedicine partners with Veristat to speed data analysis for ALS drug FDA filingClene Nanomedicine has entered a partnership with clinical research organization Veristat. Under the agreement, Veristat will apply its biostatistics platform to speed the generation and analysis…